COLUMBUS, OH., 24 February, 2011—Battelle recently won a $36.7 million contract to support the Department of Defense (DoD) in developing medical countermeasures to chemical warfare threats. The three-year contract, with the U.S. Army, includes two option years.
Battelle, the world’s largest private research and development organization, will focus on answering and validating applied and developmental biomedical questions that are critical to providing protection against existing and emerging chemical warfare threats.
The focus of this contract assisting the DoD in fully describing the medical effects of threat chemicals and to evaluate new antidotes and therapeutics for Food and Drug Administration (FDA) licensure.
Battelle has a long history of keeping military troops safe by developing defensive measures against a variety of threats.
As the world’s largest independent research and development organization, Battelle provides innovative solutions to the world’s most pressing needs through its four global businesses: Laboratory Management; National Security; Health and Life Sciences; and Energy, Environment and Material Sciences. It advances scientific discovery and application by conducting $6.2 billion in global R&D annually through contract research, laboratory management and technology commercialization.
Headquartered in Columbus, Ohio, Battelle oversees 22,000 employees in more than 130 locations worldwide, including eight national laboratories for which Battelle has a significant management role on behalf of the U.S. Department of Energy, the U.S. Department of Homeland Security, and the United Kingdom.
Battelle also is one of the nation’s leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science, technology, engineering and mathematics (STEM) education.
For more information contact Katy Delaney at (614) 424-7208 or email@example.com, or T.R. Massey at (614) 424-5544 or firstname.lastname@example.org.